Biolase, Inc.

Biolase, Inc. (NASDAQ: BIOL) develops, manufactures, markets, and sells laser systems for dental practitioners and their patients. Waterlase (all-tissue) systems and diode (soft-tissue) systems are the two types of laser systems available.

Key Highlights

• The company reported YoY growth of 76% in net revenues to USD 9.53 million in Q3FY21 (ended September 30, 2021) compared to USD 6.54 million in Q3FY20.
• BIOL reported net loss of USD 3.28 million in Q3FY21 vs. net profit of USD 123 thousand in Q3FY20.
• As of September 30, 2021, the company had cash and cash equivalents of USD 33.39 million and total debt of USD 13.51 million.
• BIOL's Q3FY21 cash cycle of 227 days is higher than the industry median of 171 days.
• Its ROE was -10.3% in Q3FY21 vs. the industry median of 1.5%.
• On January 18, 2022, BIOL announced that BIOL and BMW PCW would continue to partner to bring dentists the precision, control, and performance of the sophisticated Waterlase dental laser and BMW award-winning automobiles in FY22.
• Stock is currently trading between its crucial short-term (50-day) and long-term (200-day) SMA support levels.
• The stock is leaning towards the lower end of its 52-week range of USD 0.31 to USD 1.50.
• BIOL's stock price decreased 30.58% and 34.14% in the past six and nine months, respectively.

Technical Price Chart (as of February 08, 2022). Analysis by Kalkine

Conclusion: Considering the sharp correction in the stock price in past nine months, long-term profitability issues, technical indicators, and associated risks, we recommend a "Avoid" rating on the stock at the closing price of USD 0.4096, up 3.88%, as of February 08, 2022.

*The reference data in this report has been partly sourced from REFINITIV.

Disclaimer

The advice given by Kalkine Canada Advisory Services Inc. and provided on this website is general information only and it does not take into account your investment objectives, financial situation and the particular needs of any particular person. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. The website www.kalkine.ca is published by Kalkine Canada Advisory Services Inc. The link to our Terms & Conditions has been provided please go through them. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.